8-K: TriSalus Life Sciences Secures $50 Million Debt Financing to Fuel Growth

TriSalus Life Sciences has secured a debt financing facility of up to $50 million with OrbiMed to support the growth of its TriNav Infusion System and other strategic initiatives.

Summary

• TriSalus Life Sciences has entered into a credit agreement with OrbiMed for a senior secured credit facility of up to $50 million.
• The initial funding of $25 million was received on April 30, 2024, with an additional $25 million available in two tranches based on achieving certain revenue milestones.
• The loan matures on April 30, 2029, and carries an interest rate based on SOFR plus 8.50%, with a minimum of 4.00%, and an option to accrue up to 3.50% of interest as payable in kind for the first 15 months.
• The company issued warrants to OrbiMed to purchase 130,805 shares of common stock at an exercise price of $9.5562, with additional warrants to be issued upon funding of the delayed draw tranches.
• The company expects the financing, along with existing cash, to extend its cash runway through 2025 and aims to reach break-even EBITDA for its TriNav business in 2025.

Sentiment

Score: 7

Explanation: The document conveys a positive sentiment due to the successful securing of debt financing, which is expected to support growth and extend the cash runway. However, the presence of restrictive covenants and the need to meet revenue milestones introduce some caution.

Positives

• The $50 million debt financing provides significant capital to support strategic expansion and growth initiatives.
• The financing is expected to extend the company's cash runway through 2025.
• The company aims to reach break-even EBITDA for its TriNav business in 2025, reducing the near-term need for equity financing.
• The partnership with OrbiMed, a reputable healthcare investment firm, adds credibility and support to the company's growth plans.

Negatives

• The loan is secured by substantially all of the company's assets and those of its subsidiaries.
• The company is subject to restrictive covenants that limit its ability to take certain actions, such as incurring additional debt or making acquisitions.
• Failure to meet revenue targets related to the TriNav infusion system could trigger accelerated repayment of the loan.
• The company will be required to maintain a minimum cash balance of $5 million before March 31, 2025, and $10 million thereafter.

Risks

• The company's ability to access the additional $25 million in financing is contingent on meeting certain revenue milestones.
• Failure to comply with the terms of the credit agreement could result in an event of default and acceleration of the loan.
• The company is subject to various risks associated with clinical development and regulatory approval of its products.
• The company may need to raise additional capital through the issuance and sale of its equity securities to fund its operations if it does not reach break-even EBITDA as planned.

Future Outlook

The company expects the financing to extend its cash runway through 2025 and aims to reach break-even EBITDA for its TriNav business in 2025. The company also plans to use the funds to execute strategic growth initiatives and advance its technology pipeline.

Management Comments

• Mary Szela, Chief Executive Officer of TriSalus Life Sciences, stated that the transaction provides the needed capital to execute strategic growth initiatives for TriNav and advance the technology pipeline.
• Matthew Rizzo, General Partner of OrbiMed, expressed excitement to support TriSalus Life Sciences in pursuing their strategic objectives.

Industry Context

This debt financing is a common strategy for medical technology companies to fund growth and expansion, particularly those with promising technologies like TriSalus's PEDD approach. The investment from OrbiMed, a well-known healthcare investment firm, signals confidence in the company's potential.

Comparison to Industry Standards

• The debt financing structure, with tranches tied to revenue milestones, is a common approach in the biotech and medical device industry to mitigate risk for lenders.
• The interest rate, based on SOFR plus a margin, is typical for senior secured debt facilities in this sector.
• The issuance of warrants to the lender is also a standard practice to provide additional upside potential for the lender.
• Comparable companies in the medical device space, such as Inari Medical and Penumbra, have also utilized debt financing to support their growth initiatives.
• The goal of reaching break-even EBITDA in 2025 is a common milestone for companies in this stage of development, and is similar to the goals of other companies in the sector.

Stakeholder Impact

• Shareholders may view the debt financing positively as it provides capital for growth and reduces the near-term need for equity financing.
• Employees may benefit from the company's growth and expansion plans.
• Customers may benefit from the company's continued development of its drug delivery technology.
• Creditors are secured by the company's assets and will receive interest payments on the loan.

Next Steps

• The company will need to meet the revenue milestones to access the additional $25 million in financing.
• The company will need to file the Credit Agreement and Registration Rights Agreement as exhibits to its Quarterly Report on Form 10-Q for the quarter ending June 30, 2024.
• The company will need to prepare and file resale registration statements for the shares underlying the warrants.
• The company will need to continue to execute on its strategic growth initiatives and advance its technology pipeline.

Key Dates

Keywords

debt financing, TriNav Infusion System, OrbiMed, credit agreement, warrants, revenue milestones, cash runway, EBITDA, medical technology, oncology